EC Number   |
Substrates |
Organism |
Products |
Reversibility |
|---|
   2.4.1.62 | more |
no substrates are GM3, GM1, GD1a and GT1 gangliosides, glucocerebroside, lactosylceramide, trihexosylceramide |
Rattus norvegicus |
? |
- |
? |
| 2.4.1.62 | more |
N-acetylgalactosamine and p-nitrophenyl-N-acetylgalactosamine are no substrates |
Gallus gallus |
? |
- |
? |
| 2.4.1.62 | more |
mice heterozygous for a non-functional allele of UDPgalactose:ceramide-galactosyltransferase show decreased synthesis of galactosylceramide and sulfatide, which should reduce sulfatide storage and improve pathology in arylsulfatase A-deficient mice. The phenotypic and pathologic improvements in ASA-/- CGT+/- mice are significant but overall minor |
Mus musculus |
? |
- |
? |
| 2.4.1.62 | more |
UDPgalactose:ceramide galactosyltransferase activity does not limit total galactosylceramide level. Tight control of UDP-galactose:ceramide galactosyltransferase expression is essential for myelin maintenance |
Rattus norvegicus |
? |
- |
? |
| 2.4.1.62 | more |
GM1 ganglioside synthase B3GALT4 additionally functions in transferring galactose to the N-acetylgalactosamine side-chain of GPI. B3GALT4 requires lactosylceramide for the efficient GPI side-chain galactosylation |
Homo sapiens |
? |
- |
- |
| 2.4.1.62 | more |
no substrates are GM3, GM1, GD1a and GT1 gangliosides, glucocerebroside, lactosylceramide, trihexosylceramide |
Rattus norvegicus Sprague-Dawley |
? |
- |
? |
| 2.4.1.62 | UDP-alpha-D-galactose + BSA-conjugated C6-ceramide |
- |
Rattus norvegicus |
UDP + ? |
- |
? |
| 2.4.1.62 | UDP-Gal + GA2-FCHASE |
FCHASE: 6-(fluorescein-5-carboxamido)hexanoic acid succinimidyl ester |
Campylobacter jejuni |
? |
- |
? |
| 2.4.1.62 | UDP-Gal + GalNAcalpha-FCHASE |
FCHASE: 6-(fluorescein-5-carboxamido)hexanoic acid succinimidyl ester |
Campylobacter jejuni |
? |
- |
? |
| 2.4.1.62 | UDP-Gal + GalNAcbeta-FCHASE |
FCHASE: 6-(fluorescein-5-carboxamido)hexanoic acid succinimidyl ester |
Campylobacter jejuni |
? |
- |
? |
